Martina Del Giovane, Valentina Giunchiglia, Ziyuan Cai, Marguerite Leoni, Rebecca Street, Kirsty Lu, Andrew Wong, Maria Popham, Jennifer M. Nicholas, William Trender, Peter J. Hellyer, Thomas D. Parker, Heidi Murray-Smith, David M. Cash, Josephine Barnes, Carole H. Sudre, Paresh A. Malhotra, Sebastian J. Crutch, Marcus Richards, Adam Hampshire, Jonathan M. Schott
{"title":"Remote cognitive tests predict neurodegenerative biomarkers in the Insight 46 cohort","authors":"Martina Del Giovane, Valentina Giunchiglia, Ziyuan Cai, Marguerite Leoni, Rebecca Street, Kirsty Lu, Andrew Wong, Maria Popham, Jennifer M. Nicholas, William Trender, Peter J. Hellyer, Thomas D. Parker, Heidi Murray-Smith, David M. Cash, Josephine Barnes, Carole H. Sudre, Paresh A. Malhotra, Sebastian J. Crutch, Marcus Richards, Adam Hampshire, Jonathan M. Schott","doi":"10.1002/alz.14572","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> BACKGROUND</h3>\n \n <p>Alzheimer's disease-related biomarkers detect pathology years before symptoms emerge, when disease-modifying therapies might be most beneficial. Remote cognitive testing provides a means of assessing early cognitive changes. We explored the relationship between neurodegenerative biomarkers and cognition in cognitively normal individuals.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>We remotely deployed 13 computerized Cognitron tasks in 255 Insight 46 participants. We generated amyloid load and positivity, white matter hyperintensity volume (WMHV), whole brain and hippocampal volumes at age 73, plus rates of change over 2 years. We examined the relationship between Cognitron, biomarkers, and standard neuropsychological tests.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Slower response time on a delayed recognition task predicted amyloid positivity (odds ratio [OR] = 1.79, confidence interval [CI]: 1.15, 2.95), and WMHV (1.23, CI: 1.00, 1.56). Brain and hippocampal atrophy rates correlated with poorer visuospatial performance (<i>b </i>= -0.42, CI: -0.80, -0.05) and accuracy on immediate recognition (<i>b </i>= -0.01, CI: -0.012, -0.001), respectively. Standard tests correlated with Cognitron composites (rho = 0.50, <i>p</i> < 0.001).</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Remote computerized testing correlates with standard supervised assessments and holds potential for studying early cognitive changes associated with neurodegeneration.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>70% of the Online 46 cohort performed a set of remote online cognitive tasks.</li>\n \n <li>Response time and accuracy on a memory task predicted amyloid status and load (SUVR).</li>\n \n <li>Accuracy on memory and spatial span tasks correlated with longitudinal atrophy rate.</li>\n \n <li>The Cognitron tasks correlated with standard supervised cognitive tests.</li>\n \n <li>Online cognitive testing can help identify early AD-related memory deficits.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 2","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14572","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.14572","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND
Alzheimer's disease-related biomarkers detect pathology years before symptoms emerge, when disease-modifying therapies might be most beneficial. Remote cognitive testing provides a means of assessing early cognitive changes. We explored the relationship between neurodegenerative biomarkers and cognition in cognitively normal individuals.
METHODS
We remotely deployed 13 computerized Cognitron tasks in 255 Insight 46 participants. We generated amyloid load and positivity, white matter hyperintensity volume (WMHV), whole brain and hippocampal volumes at age 73, plus rates of change over 2 years. We examined the relationship between Cognitron, biomarkers, and standard neuropsychological tests.
RESULTS
Slower response time on a delayed recognition task predicted amyloid positivity (odds ratio [OR] = 1.79, confidence interval [CI]: 1.15, 2.95), and WMHV (1.23, CI: 1.00, 1.56). Brain and hippocampal atrophy rates correlated with poorer visuospatial performance (b = -0.42, CI: -0.80, -0.05) and accuracy on immediate recognition (b = -0.01, CI: -0.012, -0.001), respectively. Standard tests correlated with Cognitron composites (rho = 0.50, p < 0.001).
DISCUSSION
Remote computerized testing correlates with standard supervised assessments and holds potential for studying early cognitive changes associated with neurodegeneration.
Highlights
70% of the Online 46 cohort performed a set of remote online cognitive tasks.
Response time and accuracy on a memory task predicted amyloid status and load (SUVR).
Accuracy on memory and spatial span tasks correlated with longitudinal atrophy rate.
The Cognitron tasks correlated with standard supervised cognitive tests.
Online cognitive testing can help identify early AD-related memory deficits.
期刊介绍:
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.